Product Description
For the treatment of anemia in patients with chronic kidney disease of stage III-IV in systemic diseases (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17684963/)
Mechanisms of Action: ESA Activator
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Institute of Liver and Biliary Sciences, India
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Kidney Failure, Chronic|Brain Death|Acute Respiratory Distress Syndrome|Hypoxia, Brain|Hypothermia|Hepatic Insufficiency|End Stage Liver Disease|Liver Failure, Acute|Acute-On-Chronic Liver Failure
Phase 2: Stroke|Amyotrophic Lateral Sclerosis|Aortic Diseases|Hypoplastic Left Heart Syndrome|Transposition of Great Vessels
Phase 1: Urological Manifestations|Spinal Injuries
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PAEAN | P3 |
Active, not recruiting |
Acute Respiratory Distress Syndrome|Brain Death|Hypoxia, Brain|Hypothermia |
2021-03-31 |
|
| AiME - 04 | P3 |
Completed |
Kidney Failure, Chronic |
2015-02-13 |
|
| AiME - 04 | P3 |
Completed |
Kidney Failure, Chronic |
2015-02-13 |
|
| AiME - 03 | P3 |
Completed |
Kidney Failure, Chronic |
2015-01-02 |
|
| ACLF | P3 |
Completed |
Liver Failure, Acute|End Stage Liver Disease|Hepatic Insufficiency|Acute-On-Chronic Liver Failure |
2013-01-01 |